Your browser doesn't support javascript.
loading
Sulfasalazine-Induced Epstein-Barr Virus-Positive Mucocutaneous Ulcer.
Stabel, Cedric; Woei-A-Jin, F J Sherida H; Tousseyn, Thomas; Garmyn, Maria.
Afiliación
  • Stabel C; Department of Dermatology University Hospitals Leuven, Leuven, Belgium.
  • Woei-A-Jin FJSH; Department of General Medical Oncology University Hospitals Leuven KU Leuven, Leuven, Belgium.
  • Tousseyn T; Department of Pathology University Hospitals Leuven, Leuven, Belgium.
  • Garmyn M; Department of Dermatology University Hospitals Leuven, Leuven, Belgium.
Case Rep Hematol ; 2024: 6883657, 2024.
Article en En | MEDLINE | ID: mdl-38983901
ABSTRACT
Epstein-Barr virus (EBV) may cause a wide spectrum of symptomatology in humans ranging from asymptomatic upper respiratory tract infection to infectious mononucleosis and in more severe cases lymphoproliferative disorders or hemophagocytic lymphohistiocytosis. Its neoplastic potential is higher in immunocompromised individuals. We describe a case of EBV-positive mucocutaneous ulcer, a more indolent clinical entity on the spectrum of EBV-driven lymphoproliferative disorders, and are one of the first to put sulfasalazine, an immunomodulatory agent, forward as the possible culprit.

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Case Rep Hematol Año: 2024 Tipo del documento: Article País de afiliación: Bélgica

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Case Rep Hematol Año: 2024 Tipo del documento: Article País de afiliación: Bélgica